SEOM clinical guideline emesis (2021)
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau)
de las Peñas, Ramon (Hospital Provincial Castelló. Servei d'Oncologia Mèdica)
Virizuela, Juan Antonio (Hospital Universitario Virgen Macarena (Sevilla, Andalusia))
Cabezón-Gutiérrez, Luís (Hospital Universitario de Torrejón. Servicio de Oncología Médica)
Cruz, Patricia (Hospital Universitario La Paz (Madrid))
Lopez-Castro, Rafael (Hospital Clínico Universitario de Valladolid)
Méndez, Miriam (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Mondéjar, Rebeca (Hospital Universitario de La Princesa. Servicio de Oncología Médica)
Muñoz, María del Mar (Hospital Virgen de La Luz (Cuenca))
Escobar, Yolanda (Hospital General Universitario Gregorio Marañón)

Date:	2022
Abstract:	Among the side effects of anticancer treatment, chemotherapy-induced nausea and vomiting (CINV) is one of the most feared given its high prevalence, affecting up to 40% of patients. It can impair patient's quality of life and provoke low adherence to cancer treatment or chemotherapy dose reductions that can comprise treatment efficacy. Suffering CINV depends on factors related to the intrinsic emetogenicity of antineoplastic drugs and on patient characteristics. CINV can appear at different times regarding the administration of antitumor treatment and the variability of risk according to the different antitumor regimens has, as a consequence, the need for a different and adapted antiemetic treatment prophylaxis to achieve the desired objective of complete protection of the patient in the acute phase, in the late phase and in the global phase of emesis. As a basis for the recommendations, the level of emetogenicity of anticancer treatment is considered and they are classified as high, moderate, low and minimal emetogenicity and these recommendations are based on the use of antiemetic drugs with a high therapeutic index: anti 5-HT, anti-NK and steroids. Despite having highly effective treatments, clinical reality shows that they are not applied enough, so evidence-based recommendations are needed to show the best options and help in decision-making. To cover all the antiemetic prophylaxis options, we have also included recommendations for oral treatments, multiday regimens and radiation-induced emesis prevention.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Emesis ; Nausea ; Vomiting ; Chemotherapy
Published in:	Clinical & translational oncology, Vol. 24 Núm. 4 (april 2022) , p. 712-723, ISSN 1699-3055

DOI: 10.1007/s12094-022-02802-1
PMID: 35347571

12 p, 719.9 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles